Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Inclusion Criteria:

* Confirmed diagnosis of hepatocellular carcinoma
* Surgical evaluation by a member of the Liver Tumor Program must conclude the patient is not a candidate for resection or ablation
* Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0-2
* Able to comprehend and provide written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:

* Absolute granulocyte count =\<1,500/ul
* Platelet count =\<75,000/ul
* Serum creatinine \>= 2.0 mg/dl
* Serum bilirubin

  * \>= 2.0 mg/dl for bilateral treatment or lobar treatment
  * \>= 3.0 mg/dl for single lesion which could be treated by segmental fusion
* History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine
* Bleeding, diathesis not correctable by usual forms of therapy
* Severe peripheral vascular disease that would preclude catheterization
* Portal hypertension with portal venous shunt away from the liver
* Evidence of potential delivery greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:

  1. first TheraSphere administration; or
  2. cumulative delivery of radiation to the lungs \> 30 Gy over multiple treatments
* Evidence of any detectable Tc-99m MMA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow
* Significant extrahepatic disease representing an imminent life-threatening outcome
* Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency (requiring continuous oxygen therapy)
* Active uncontrolled infection
* Significant underlying medical or psychiatric illness
* Pregnant women may not participate
* Children may not participate